SG10202009849WA - Gene therapy for treating hemophilia a - Google Patents

Gene therapy for treating hemophilia a

Info

Publication number
SG10202009849WA
SG10202009849WA SG10202009849WA SG10202009849WA SG10202009849WA SG 10202009849W A SG10202009849W A SG 10202009849WA SG 10202009849W A SG10202009849W A SG 10202009849WA SG 10202009849W A SG10202009849W A SG 10202009849WA SG 10202009849W A SG10202009849W A SG 10202009849WA
Authority
SG
Singapore
Prior art keywords
gene therapy
treating hemophilia
hemophilia
treating
therapy
Prior art date
Application number
SG10202009849WA
Inventor
Lili Wang
James M Wilson
Jenny Agnes Sidrane
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG10202009849WA publication Critical patent/SG10202009849WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10202009849WA 2016-04-15 2017-04-13 Gene therapy for treating hemophilia a SG10202009849WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323336P 2016-04-15 2016-04-15
US201662331807P 2016-05-04 2016-05-04
US201662428866P 2016-12-01 2016-12-01

Publications (1)

Publication Number Publication Date
SG10202009849WA true SG10202009849WA (en) 2020-11-27

Family

ID=59253992

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808422QA SG11201808422QA (en) 2016-04-15 2017-04-13 Gene therapy for treating hemophilia a
SG10202009849WA SG10202009849WA (en) 2016-04-15 2017-04-13 Gene therapy for treating hemophilia a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201808422QA SG11201808422QA (en) 2016-04-15 2017-04-13 Gene therapy for treating hemophilia a

Country Status (16)

Country Link
US (3) US11779656B2 (en)
EP (1) EP3452102B1 (en)
JP (2) JP7347933B2 (en)
KR (1) KR102450833B1 (en)
CN (1) CN109562191A (en)
AU (1) AU2017248659B2 (en)
BR (1) BR112018071200A2 (en)
CA (1) CA3019425A1 (en)
IL (1) IL262215B2 (en)
MX (1) MX2018012537A (en)
PE (1) PE20181922A1 (en)
RU (1) RU2762257C2 (en)
SA (1) SA518400233B1 (en)
SG (2) SG11201808422QA (en)
TW (1) TWI791433B (en)
WO (1) WO2017180857A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191847B2 (en) 2016-04-15 2021-12-07 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia B
JOP20210054A1 (en) * 2018-09-21 2020-03-21 Nightstarx Ltd Compositions and methods for treating retinitis pigmentosa
US20210324483A1 (en) * 2018-10-15 2021-10-21 Regenxbio Inc. Method for measuring the infectivity of replication defective viral vectors and viruses
EP3930765A1 (en) * 2019-02-26 2022-01-05 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
SG11202109850SA (en) * 2019-03-13 2021-10-28 Generation Bio Co Non-viral dna vectors and uses thereof for expressing fviii therapeutics
US20220396610A1 (en) * 2019-11-01 2022-12-15 Freeline Therapeutics Limited Factor viii polypeptide
CN111218446B (en) * 2019-12-25 2023-03-28 劲帆生物医药科技（武汉）有限公司 Liver specificity promoter and application thereof
IL298138A (en) 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2022165246A1 (en) * 2021-01-29 2022-08-04 The Trustees Of The University Of Pennsylvania Compositions and method of use of mutant ace2 decoy variants
MX2023008826A (en) 2021-02-01 2023-09-15 Regenxbio Inc Gene therapy for neuronal ceroid lipofuscinoses.
AU2022214529A1 (en) * 2021-02-01 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of niemann pick type a disease
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2023205300A2 (en) * 2022-04-20 2023-10-26 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
WO2023240222A2 (en) * 2022-06-10 2023-12-14 University Of Florida Research Foundation, Incorporated Immune tolerance induction to viral capsids

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5439824A (en) 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
JP2002517180A (en) 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン Novel vectors and genes exhibiting increased expression
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US6797505B2 (en) 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
US6610906B1 (en) 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
CA2387484A1 (en) 1999-10-12 2001-04-19 Haim Burstein Adeno-associated virus vectors encoding factor viii and methods of using the same
EP1232276B8 (en) 1999-11-16 2007-06-27 Genzyme Corporation Vectors and transgenes with regulatory elements for gene delivery to the liver
NZ521732A (en) 2000-03-22 2004-05-28 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines and factor VIII muteins
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US7351813B2 (en) 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030147853A1 (en) 2001-03-14 2003-08-07 Mcclelland Alan Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
JP4634036B2 (en) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー Nucleic acid and amino acid sequences encoding high level expressor factor VIII polypeptides and methods of use
EP2338900B1 (en) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
AU2002360291A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
WO2005013090A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for biopolymer engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
DK1673391T3 (en) 2003-10-16 2009-04-06 Claude Negrier Modified cDNA for high expression levels of factor VIII and its derivatives
WO2005055930A2 (en) 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
EP1804839B1 (en) 2004-09-22 2012-03-14 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
US8008468B2 (en) 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
WO2006102072A2 (en) 2005-03-23 2006-09-28 The Trustees Of The University Of Pennsylvania Use of a pa131 polypeptide in treatment of atherosclerosis
AU2006233638A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
WO2007016331A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Classification and diagnosis of the molecular basis of cholestasis
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
EP2021499A4 (en) 2005-12-16 2010-02-17 Univ Leland Stanford Junior Functional arrays for high throughput characterization of gene expression regulatory elements
EP1979485A2 (en) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
US8129510B2 (en) 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
WO2007149852A2 (en) 2006-06-19 2007-12-27 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP2118320A4 (en) 2007-02-06 2010-05-19 Genizon Biosciences Inc Genemap of the human genes associated with adhd
US8309698B2 (en) 2008-02-14 2012-11-13 Mogam Biotechnology Research Institute Expression vector suitable for expression of a coding sequence for gene therapy
KR100981092B1 (en) 2008-02-29 2010-09-08 고려대학교 산학협력단 Recombinant expression vector system for variants of coagulation factor VIII and von Willebrand factor
WO2009122401A2 (en) 2008-04-03 2009-10-08 Yeda Research And Development Co. Ltd. Methods of expressing a polypeptide in the brain and nucleic acid constructs capable of same
WO2009130208A1 (en) 2008-04-22 2009-10-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
AU2009262104A1 (en) 2008-06-25 2009-12-30 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of osteoarthritis
KR101034811B1 (en) 2008-08-25 2011-05-16 단국대학교 산학협력단 Recombinant adenovirus comprising tissu-specific promoter and tumor-targeting trans-splicing ribozyme and uses thereof
MX2011010097A (en) 2009-03-27 2011-10-19 Proyecto Biomedicina Cima Sl Methods and compositions for the treatment of cirrhosis and liver fibrosis.
CN101935674A (en) * 2009-06-30 2011-01-05 中国医学科学院血液学研究所 Adenovirus vector for gene therapy on hemophilia B and application thereof
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
EP2542247A4 (en) 2010-03-01 2014-05-07 Philadelphia Children Hospital Nucleic acids for targeting multiple regions of the hcv genome
US9315825B2 (en) * 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
AU2011238708B2 (en) 2010-03-29 2016-02-11 The Trustees Of The University Of Pennsylvania Pharmacologically Induced Transgene Ablation system
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
EP2480678B1 (en) * 2010-09-02 2014-02-12 Molmed SpA Stable production of lentiviral vectors
FR2977562B1 (en) 2011-07-06 2016-12-23 Gaztransport Et Technigaz SEALED AND THERMALLY INSULATING TANK INTEGRATED IN A CARRIER STRUCTURE
EP3513802B1 (en) * 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
JP6454643B2 (en) 2012-10-26 2019-01-16 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ Vectors and methods and uses for liver-directed gene therapy for hemophilia
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
PL3044231T3 (en) * 2013-09-12 2021-01-11 Biomarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii
CN107531774B (en) * 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 Optimized human coagulation factor VIII gene expression cassette and application thereof
EP3288594B1 (en) * 2015-04-27 2022-06-29 The Trustees of The University of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
KR20230008256A (en) * 2015-11-13 2023-01-13 다케다 야쿠힌 고교 가부시키가이샤 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3387118B1 (en) 2015-12-11 2022-04-06 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10

Also Published As

Publication number Publication date
RU2018136611A (en) 2020-05-15
MX2018012537A (en) 2019-02-25
US20200085975A1 (en) 2020-03-19
US11779656B2 (en) 2023-10-10
RU2762257C2 (en) 2021-12-17
AU2017248659A1 (en) 2018-10-18
KR20190032274A (en) 2019-03-27
JP2022062121A (en) 2022-04-19
EP3452102B1 (en) 2024-06-12
CN109562191A (en) 2019-04-02
SA518400233B1 (en) 2022-08-23
EP3452102A1 (en) 2019-03-13
IL262215B1 (en) 2023-03-01
CA3019425A1 (en) 2017-10-19
JP2019513794A (en) 2019-05-30
WO2017180857A1 (en) 2017-10-19
IL262215B2 (en) 2023-07-01
KR102450833B1 (en) 2022-10-05
TW201741458A (en) 2017-12-01
US10888628B2 (en) 2021-01-12
US20240000974A1 (en) 2024-01-04
AU2017248659B2 (en) 2022-08-11
JP7347933B2 (en) 2023-09-20
PE20181922A1 (en) 2018-12-11
TWI791433B (en) 2023-02-11
BR112018071200A2 (en) 2019-04-09
US20190343966A1 (en) 2019-11-14
IL262215A (en) 2018-11-29
SG11201808422QA (en) 2018-10-30
RU2018136611A3 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
SG10202009849WA (en) Gene therapy for treating hemophilia a
IL260959A (en) Gene therapy for treating mucopolysaccharidosis type i
IL284741B (en) Gene therapy for retinitis pigmentosa
IL258580B (en) Combination therapy for treating malignancies
IL284577A (en) Gene therapy
IL258685B (en) Combination therapy for treating malignancies
IL262211A (en) Gene therapy for treating mucopolysaccharidosis type ii
IL258269A (en) Combination therapy for treating malignancies
IL258684A (en) Combination therapy for treating malignancies
IL259850A (en) Gene therapy for treating familial hypercholesterolemia
GB201707212D0 (en) Gene therapy for ciliopathies
IL263085A (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
AP2016009066A0 (en) A drug for treating cancer